Revenue Performance - Fourth quarter 2025 revenue was $4.8 million, down from $8.5 million in Q4 2024, while full year revenue decreased to $27.9 million from $38.1 million in 2024[4]. - Bookings in Q4 2025 were $3.4 million, down 21% year-over-year, while full year bookings totaled $26.1 million, a decrease of 34%[8]. Profitability and Loss - Net loss for Q4 2025 was ($7.3) million compared to ($3.6) million in Q4 2024, with a full year net loss of ($25.4) million versus ($20.8) million in 2024[10]. - Operating expenses in Q4 2025 were $6.5 million, up from $5.9 million in Q4 2024, with full year operating expenses at $28.3 million compared to $25.5 million in 2024[9]. Revenue Composition - Software and services accounted for 53% of revenue in Q4 2025, up from 43% in Q4 2024, contributing to a gross margin increase of 840 basis points to 49%[4][7]. - Annualized Contract Value (ACV) of renewable software at December 31, 2025, was $9.9 million, representing a 12% decrease year-over-year[7]. - Net Dollar Revenue Retention (NDRR) was 71% for customers with over $50,000 of ACV as of December 31, 2025, compared to the same customers a year prior[8]. Strategic Initiatives - zSpace launched the zStylus One on November 18, 2025, enhancing AR deployment capabilities across its product lines[4]. - The company completed a strategic restructuring initiative on December 11, 2025, reducing operating expenses by over 30%[4][5]. - zSpace announced a $3 million strategic investment from Planet One Education on January 29, 2026, aimed at enhancing liquidity and supporting international collaboration[12].

Financial Performance - The company has incurred net losses of $138.0 million and $68.0 million for the years ended December 31, 2025 and 2024, respectively, and has not generated any revenue from product sales to date [222]. - As of December 31, 2025, the company had $414.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the first half of 2029 [227]. - The February 2026 Offering resulted in net proceeds of approximately $161.8 million after deducting underwriting discounts and commissions [233]. - The company plans to finance operations through existing cash and potential future equity or debt financings, which may dilute stockholder ownership [231]. - The company has not yet demonstrated an ability to generate revenue or obtain regulatory approval for any product, which poses significant risks to its future success [221]. Development and Regulatory Risks - The company anticipates significant increases in expenses as it advances ficerafusp alfa through clinical development and seeks regulatory approvals [223]. - The company is highly dependent on the success of ficerafusp alfa, and any delays or failures in its development could materially harm its business [237]. - The company expects to incur significant commercialization expenses if ficerafusp alfa is approved for sale, making profitability difficult to predict [230]. - The company may face unforeseen expenses and difficulties in achieving its business objectives, which could adversely affect its financial condition [224]. - The regulatory approval process is lengthy and unpredictable, typically taking many years, which may delay commercialization of product candidates [337]. Competition and Market Position - The biotechnology industry is highly competitive, with major pharmaceutical companies having greater financial and technical resources, which could impact the company's market position [239]. - Competitors may obtain regulatory approvals more rapidly and develop more effective or cost-efficient products, potentially limiting the company's ability to commercialize ficerafusp alfa [240]. - The company faces competition from established therapies for head and neck squamous cell carcinoma (HNSCC), including pembrolizumab and cetuximab, as well as numerous other companies developing new treatments [241]. Clinical Trials and Development Challenges - The company initiated the Phase 2/3 FORTIFI-HN01 pivotal trial of ficerafusp alfa in combination with pembrolizumab for first-line recurrent/metastatic HPV-negative HNSCC [246]. - Clinical development for ficerafusp alfa is lengthy and costly, with uncertain outcomes that could delay or prevent commercialization [274]. - There is a risk of delays in clinical trials due to various factors, including regulatory requirements and unforeseen safety issues [276]. - The company must demonstrate the safety, purity, and potency of its product candidates through extensive testing before obtaining regulatory approvals [289]. - The integrity of clinical trial data may be questioned due to potential conflicts of interest among principal investigators [279]. Compliance and Legal Risks - The company is subject to various privacy and data security laws, which may incur substantial compliance costs and expose it to significant penalties for noncompliance [252]. - Non-compliance with GDPR could result in fines of up to €20 million or 4% of annual global revenues, whichever is greater, impacting the company's financial position [258]. - The company is currently involved in litigation regarding its intellectual property, which could be costly and time-consuming, potentially impacting its business operations [402]. - The company may not have sufficient resources to effectively conduct litigation against competitors, which could hinder its ability to compete in the marketplace [405]. Intellectual Property and Patent Risks - The patent prosecution process is time-consuming and costly, and failure to secure adequate patent protection could adversely affect market competitiveness [391]. - There is a risk that issued patents covering ficerafusp alfa could be found invalid or unenforceable if challenged, which may allow competitors to commercialize similar technologies [402]. - The biotechnology industry is characterized by significant patent litigation, which could absorb substantial management time and resources, impacting overall business strategy [408]. - The outcome of patent litigation is unpredictable, and adverse rulings could materially harm the company's business and competitive position [404]. Strategic Partnerships and Collaborations - The company has collaborations with MSD International GmbH and Biocon Ltd for the development and commercialization of ficerafusp alfa, which may pose risks if collaborations are not successful [316]. - Future collaborations may require substantial additional cash, and failure to establish them on commercially reasonable terms could alter development plans [318]. - The company faces significant competition in securing strategic partners, and negotiations can be complex and time-consuming [319]. Manufacturing and Supply Chain Risks - The company primarily relies on WuXi Biologics for production, and any need for alternative manufacturers could incur added costs and delays [330]. - The reliance on third-party suppliers for production may impair research and development programs, and any failure to meet regulatory standards could delay commercialization [325]. - Geopolitical tensions and regulatory scrutiny regarding relationships with Chinese biotechnology companies could impact supply chains and operations [331].

Financial Performance - Revenue for Q1 2026 was $247.8 million, representing a 4% increase year-over-year[5] - Operating income increased by 43% to $46.5 million, with an operating margin of 19%, up from 14% in Q1 2025[5][6] - Net income surged 108% to $22.8 million, with diluted earnings per share rising 121% to $0.53[5][6] - Cash from operations for Q1 2026 was $98.6 million, a 43% increase compared to $68.9 million in Q1 2025[5][6] - GAAP income from operations increased to $46,465,000 in Q1 2026 from $32,426,000 in Q1 2025, representing a growth of 43%[18] - Non-GAAP income from operations rose to $102,185,000 in Q1 2026, compared to $93,595,000 in Q1 2025, reflecting a year-over-year increase of 9%[18] - Adjusted free cash flow for Q1 2026 was $98,845,000, up 35% from $73,211,000 in Q1 2025[19] - GAAP diluted earnings per share improved to $0.53 in Q1 2026, compared to $0.24 in Q1 2025, marking a 121% increase[18] - Non-GAAP diluted earnings per share for Q1 2026 reached $1.60, up from $1.31 in Q1 2025, indicating a growth of 22%[18] Guidance and Projections - The company expects FY 2026 revenue guidance of $988 million to $1 billion, with diluted earnings per share projected between $1.71 and $1.87[9] - Operating margin guidance for FY 2026 is set at 16% to 17%, with non-GAAP operating margin expected to be 39%[9] - Fiscal Year 2026 guidance projects GAAP income from operations between $162 million and $170.4 million, with a GAAP operating margin of 16% to 17%[20] - Non-GAAP net income guidance for Fiscal Year 2026 is estimated between $254.7 million and $262.2 million[21] - Unlevered free cash flow guidance for Fiscal Year 2026 is projected to be between $315 million and $326 million[23] - The company expects a non-GAAP operating margin of 39% for Fiscal Year 2026[20] Cash and Capital Management - Cash and cash equivalents at the end of Q1 2026 were $113.2 million, up from $94.8 million at the end of Q4 2025[7][16] - The company plans to continue debt paydown and share buybacks as part of its capital return strategy[4][6] - Cash flows from operations increased to $98,626,000 in Q1 2026, a 43% rise from $68,947,000 in Q1 2025[19] Revenue Recognition and Metrics - The company recognizes revenue from term-based licenses and on-premises subscriptions upfront at the point control is transferred, in accordance with ASC 606[30] - Annual Recurring Revenue (ARR) is calculated based on existing contracts and is not defined by GAAP, aligning more closely with billings rather than recognized revenue[32] - Annualized Recurring Revenue (ARR) reached $863 million, a 2% increase year-over-year on a constant currency basis[6] - The Net Retention Rate (NRR) is calculated by comparing ARR from the same customer cohort over a 12-month period, reflecting expansions and contractions but excluding new customer ARR[33] Risks and Challenges - Forward-looking statements indicate potential risks including economic conditions, international sales challenges, and cybersecurity threats that could materially affect financial results[34] - The company emphasizes that future acquisitions may involve unanticipated costs or integration issues that could disrupt operations[34] Balance Sheet Strength - Progress Software's balance sheet remains strong, supporting long-term value creation investments[6]

Financial Performance - Net sales for the three months ended February 28, 2026, were $926.6 million, a 5.7% increase from $876.2 million for the same period last year[8] - Gross margin increased to $352.9 million for the three months ended February 28, 2026, compared to $332.4 million for the same period last year, reflecting a gross margin percentage improvement[8] - Operating earnings for the nine months ended February 28, 2026, were $146.9 million, a significant recovery from an operating loss of $4.5 million for the same period last year[8] - Net earnings attributable to MillerKnoll, Inc. for the three months ended February 28, 2026, were $23.5 million, compared to a net loss of $12.7 million for the same period last year[8] - For the nine months ended February 28, 2026, net earnings increased to $20.2 million from a previous period, with a subsequent increase to $24.2 million in the following quarter[13] - Total revenue for the three months ended February 28, 2026, was $926.6 million, an increase from $876.2 million for the same period in 2025, representing a growth of 5.4%[28] - For the nine months ended February 28, 2026, total revenue reached $2,837.5 million, compared to $2,708.1 million in the prior year, reflecting an increase of 4.8%[28] Cash and Liquidity - Cash and cash equivalents decreased to $174.6 million as of February 28, 2026, from $193.7 million as of May 31, 2025[9] - The total cash and cash equivalents at the end of the period decreased to $174.6 million from $193.7 million at the beginning of the period, reflecting a net decrease of $19.1 million[12] - The company reported a net cash provided by operating activities of $135.1 million for the nine months ended February 28, 2026, compared to $138.4 million for the same period last year[11] - The company experienced a net cash used in financing activities of $83.8 million, compared to $127.6 million in the previous period[12] - The Company reported a net cash position of $0.9 million as of February 28, 2026, down from $1.4 million as of May 31, 2025[34] Assets and Liabilities - Total assets increased slightly to $3,951.6 million as of February 28, 2026, compared to $3,950.2 million as of May 31, 2025[9] - Total liabilities decreased to $2,553.2 million as of February 28, 2026, from $2,615.1 million as of May 31, 2025[9] - The carrying value of total debt as of February 28, 2026, was $1,310.1 million, with a fair value of $1,318.8 million[60] - The Company has a total debt of $1,310.1 million as of February 28, 2026, down from $1,337.0 million on May 31, 2025[86] Shareholder Information - The company declared dividends of $0.1875 per share, totaling $13.1 million for the period[13] - The total number of common shares outstanding as of February 28, 2026, was 68,383,040, reflecting a slight increase from 68,249,980 shares[13] - Basic earnings per share for the three months ended February 28, 2026, was $0.34, compared to a loss of $(0.19) for the same period in 2025[53] Operational Efficiency - Capital expenditures for the nine months ended February 28, 2026, were $83.4 million, an increase from $68.1 million for the same period last year[11] - The company plans to continue focusing on restructuring and integration efforts to improve operational efficiency and profitability moving forward[8] - Restructuring charges totaled $2.2 million and $4.2 million for the three and nine months ended February 28, 2026, respectively[118] - The company recorded a total of $144.4 million in pre-tax integration expenses related to the Knoll Integration program, with no future costs expected[115] Market Segments - North America Contract revenue for the three months ended February 28, 2026, was $488.6 million, up from $468.2 million in the same period last year, a growth of 2.9%[28] - International Contract revenue increased to $156.9 million for the three months ended February 28, 2026, compared to $145.5 million in the prior year, marking a growth of 7.7%[28] - Global Retail revenue for the three months ended February 28, 2026, was $281.1 million, a rise of 7.1% from $262.5 million in the previous year[28] - The Lifestyle product category generated $217.1 million in revenue during the three months ended February 28, 2026, compared to $201.5 million in the same period last year, an increase of 7.6%[28] Goodwill and Impairment - Goodwill increased to $1,167.2 million as of February 28, 2026, from $1,152.4 million at the end of the previous fiscal year[36] - The company recognized $37.7 million in non-cash impairment charges related to the Knoll and Muuto trade names during Q3 of fiscal year 2025[50] - A decrease in operating margin of 100 basis points would result in impairment of $3.0 million for the Coverings reporting unit[47] - The company reassigned $26.1 million of goodwill from the Americas Contract reporting unit to the International Contract reporting unit[48] Tax and Compliance - The effective tax rates were 19.2% for the three months ended February 28, 2026, compared to 88.3% for the same period in 2025[56] Financial Instruments and Debt Management - The Company entered into an interest rate swap agreement in September 2016 for a notional amount of $150.0 million, converting a LIBOR-based floating interest rate to a 1.910% fixed interest rate[72] - A second interest rate swap agreement was established in June 2017 for a notional amount of $75.0 million, locking in a fixed interest rate of 2.348%[73] - In January 2022, the Company executed a third interest rate swap for $575.0 million, fixing the interest rate at 1.650%[74] - A fourth interest rate swap agreement was entered into in February 2023 for $150.0 million, with a fixed interest rate of 3.950%[75] - The Company’s interest rate swap agreements were amended in February 2023 to replace LIBOR with a Term SOFR rate, resulting in modified fixed rates of 1.910%, 2.348%, and 1.650% for previous swaps[78] Other Comprehensive Income - Other comprehensive income for the nine months ended February 28, 2026, was reported at $12.7 million, with a subsequent loss of $12.9 million in the following quarter[13] - The company’s accumulated other comprehensive loss decreased to $(64.9) million as of February 28, 2026, from $(82.2) million[13] - The Company recognized a loss of $3.9 million in other comprehensive income for the three months ended February 28, 2026, and a total loss of $12.9 million for the nine months ended[79] - The expected gain to be reclassified from Accumulated other comprehensive income into earnings in the next twelve months is $11.6 million, net of tax $8.8 million[79]

Revenue Recognition and Financial Performance - The company recognizes revenue from subscription agreements ratably over typically one-year terms, leading to potential delays in reflecting downturns in operating results[83]. - A significant portion of the company's revenue is derived from government contracts, which are subject to risks such as early termination and audits[84]. - Compliance with federal securities laws results in higher expenses compared to privately held companies, impacting growth resources[86]. - The company does not expect to pay any dividends on its common stock for the foreseeable future, as it plans to retain earnings to maintain and expand operations[103]. Legal and Compliance Risks - The company may face substantial expenditures due to indemnification obligations for directors and officers, which could discourage litigation against them[87]. - Security breaches could lead to loss of confidential information and significant liabilities, affecting the company's reputation and business[88]. - The company may experience increased costs and operational disruptions due to potential litigation related to intellectual property claims[92]. - The Financial Industry Regulatory Authority's sales practice requirements may limit the ability of shareholders to buy and sell the company's stock[101]. Market and Economic Conditions - Future sales of shares by stockholders under Rule 144 may adversely affect the market price of the company's common stock[99]. - The company's common stock may experience significant price fluctuations, which could lead to losses for shareholders[100]. - Global economic uncertainty, including high interest rates and fluctuating raw material costs, is expected to adversely impact customer technology purchases and contract negotiations[104]. - The company’s IntelliCloud Payables Automation Solution is targeted at industries like home-building and construction, which are currently facing low demand due to economic conditions[104]. Operational Challenges - The company is vulnerable to disruptions at third-party data centers, which could lead to service interruptions and negatively affect revenue and customer retention[106]. - Attracting and retaining top employees is critical for the company’s success, with intense competition for skilled personnel leading to potential increased compensation costs[108]. - The company relies on a combination of intellectual property laws and contractual provisions to protect its proprietary technology, but faces challenges from software piracy and competition[109].

Clinical Development - Pelareorep demonstrated a 33% objective response rate (ORR) in second-line metastatic colorectal cancer (mCRC) compared to approximately 10% with standard-of-care, with a median progression-free survival (PFS) of 16.6 months versus 5.7 months[259]. - In the GOBLET Cohort 4 study for second-line squamous cell carcinoma of the anal canal (SCAC), pelareorep and atezolizumab achieved a 30% ORR, significantly higher than the 13.8% ORR of the current standard of care[263]. - A randomized Phase 2 study for second-line RAS-mutated mCRC patients is expected to initiate in late March 2026, with preliminary data anticipated by year-end[260]. - The company is focusing on advancing pelareorep as a platform immunotherapy for gastrointestinal cancers, with plans for registration-enabled clinical studies in metastatic colorectal cancer and pancreatic cancer[254]. - The company anticipates meeting with the FDA in mid-April 2026 to discuss a registrational study design for second-line or later SCAC in the U.S.[263]. Financial Performance - The company reported a net loss of $28,759 for the year ended December 31, 2025, compared to a net loss of $22,794 in 2024, reflecting an increase of $5,965[284]. - Cash and cash equivalents decreased from $11,079 in 2024 to $5,202 in 2025, indicating a significant reduction in liquidity[294]. - Net cash used in operating activities was $20,112 in 2025, slightly higher than $19,883 in 2024, primarily related to funding R&D activities[295]. - The company recognized a fair value loss of $388 from the SEPA Arrangement after selling 6,650,000 common shares for gross proceeds of $2,348 at an average price of $0.35[291]. - Foreign exchange losses amounted to $106 in 2025, compared to gains of $699 in 2024, reflecting fluctuations in currency exchange rates[292]. Funding and Liquidity - As of December 31, 2025, the company had cash and cash equivalents of $5,202, raising concerns about its ability to continue as a going concern without additional financing[277][255]. - The company expects to continue incurring substantial operating losses until future product sales or licensing fees become sufficient to fund operations[302]. - The company plans to raise additional funds through the sale of common shares or other capital resources, but there is no assurance that additional liquidity will be available under acceptable terms[306]. - If adequate funding is not secured, the company may need to scale back operations, including cost reduction strategies and potentially relinquishing rights to its technology[309]. - The company has approximately $39,002 remaining on its $50,000 ATM facility, which is intended to support near-term capital objectives[304]. Expenses and Obligations - Research and development (R&D) expenses decreased by $2,129 from $15,443 in 2024 to $13,314 in 2025, primarily due to lower clinical trial costs[285]. - General and administrative (G&A) expenses increased by $5,312 from $10,099 in 2024 to $15,411 in 2025, driven by higher public company-related expenses and personnel-related costs[287]. - The company has contractual obligations of approximately $1.248 million related to clinical trial and contract manufacturing programs expected to occur over the next two years[311]. - Clinical trial and manufacturing expenses are significant components of the company's R&D expenses, with payments dependent on achieving certain milestones[315]. Strategic Initiatives - The company is actively evaluating strategic partnership options to support its clinical programs and enhance the development of pelareorep[271]. - Manufacturing capabilities are being expanded to support clinical development, with a cGMP production run executed in 2025 and ongoing process validation activities[272]. - The company has not recognized any deferred tax assets due to a history of losses and uncertainties regarding future taxable income[320]. - The number of outstanding warrants remained at 7,667,050 as of December 31, 2025, with no cash flow impact from changes in their fair value[290]. - The company raised net cash proceeds of $14.115 million from the issuance of 22,999,857 common shares through its ATM offering agreements and SEPA Arrangement for the year ended December 31, 2025[310]. Going Concern - There is substantial doubt about the company's ability to continue as a going concern over the next 12 months due to uncertainties in funding requirements and operational expenditures[307]. - Management's estimates and assumptions regarding capital requirements and financial statements may prove to be incorrect, leading to material variances from expectations[307]. - The company may face dilution of shareholders' ownership interest if additional capital is raised through equity or convertible debt securities[308]. - The company has not entered into any off-balance sheet arrangements as of December 31, 2025[312].

Financial Performance - Total product revenues for 2025 reached $1,005,471, a 65.3% increase from $607,574 in 2024[375] - Gross profit for 2025 was $223,776, slightly up from $222,809 in 2024, indicating stable profitability despite increased revenues[375] - The net loss attributed to 60 Degrees Pharmaceuticals, Inc. for 2025 was $7,365,158, compared to a loss of $7,947,107 in 2024, representing a 7.3% improvement[376] - For the year ended December 31, 2025, the net loss was $7,368,325, compared to a net loss of $7,955,663 for the year ended December 31, 2024, representing a decrease of approximately 7.4%[385] - The total loss before income taxes for 2025 was $(7,368,325), a slight improvement from $(7,955,663) in 2024[517] Expenses and Costs - Research and development expenses decreased to $2,106,156 in 2025 from $4,986,526 in 2024, reflecting a strategic shift in resource allocation[375] - Total operating expenses for 2025 were $8,385,979, down from $10,011,761 in 2024, showing a reduction of approximately 16.3%[375] - Share-based compensation expense for the year ended December 31, 2025, was $279,873, significantly higher than $32,767 in 2024, reflecting an increase of over 754%[385] - The depreciation expense increased to $43,324 in 2025 from $11,726 in 2024, showing a rise of approximately 269%[385] - Operating lease costs for the years ended December 31, 2025, and 2024 were $20,350 and $28,867, respectively[538] Assets and Liabilities - Cash and cash equivalents decreased to $1,510,065 in 2025 from $1,659,353 in 2024, indicating a need for improved liquidity management[373] - Total assets declined to $5,366,211 in 2025 from $5,759,345 in 2024, a decrease of approximately 6.8%[373] - Total liabilities increased to $1,986,795 in 2025 from $1,804,339 in 2024, marking an increase of about 10.1%[373] - The accumulated deficit grew to $47,893,115 in 2025 from $40,527,957 in 2024, highlighting ongoing financial challenges[373] - The total shareholders' equity as of December 31, 2025, was $3,379,416, a decrease from $3,955,006 as of December 31, 2024, indicating a decline of about 14.6%[381] Cash Flow - The company reported a net cash used in operating activities of $6,849,022 for the year ended December 31, 2025, compared to $5,648,088 for the previous year[392] - The company had net cash provided by financing activities of $6,437,691, a decrease from $7,053,571 in the prior year[392] - The company’s cash flows from operating activities showed a net loss of $7,368,325 for 2025, which is an improvement compared to the previous year's loss of $7,955,663[385] Stock and Equity - The weighted average number of common shares outstanding increased to 670,211 in 2025 from 113,665 in 2024, reflecting changes in capital structure[376] - The Company has authorized 150,000,000 shares of common stock and 1,000,000 shares of preferred stock, with 1,163,142 shares of common stock and 76,480 shares of Series A Preferred Stock issued and outstanding as of December 31, 2025[469] - The Company executed a 1:12 Reverse Stock Split on August 12, 2024, reducing outstanding shares from 21,219,937 to 1,768,337[470] - Following a 1:5 Reverse Stock Split on February 24, 2025, the number of outstanding shares decreased from 7,364,554 to 1,472,891[471] - A 1:4 Reverse Stock Split was implemented on January 20, 2026, further reducing shares from 5,436,441 to 1,359,091[472] Revenue Recognition - The Company recognizes revenue from product sales when control is transferred, with the majority of revenues coming from sales of its Arakoda™ product[433] - The Company recognizes research revenues associated with its contract with the US Army Medical Materiel Development Activity, with revenue recognized when eligible costs are incurred[434] Inventory and Assets Management - The company reported a change in inventory reserve of $251,677 for the year ended December 31, 2025, compared to no change in 2024, indicating a strategic adjustment in inventory management[385] - As of December 31, 2025, the total inventory amounted to $656,924, an increase from $442,764 in 2024, with raw materials valued at $75,662, work in process at $446,957, and finished goods at $385,982[464] Future Outlook and Risks - The company plans to fund operations through third-party debt, private placements, and stock issuances until achieving profitability[395] - The company is subject to significant risks, including the ability to obtain regulatory approvals and competition in the biopharmaceutical industry[390] - The company’s future results are uncertain, and there is substantial doubt about its ability to continue as a going concern for one year from the issuance of the financial statements[396] Tax and Deferred Assets - The Company has established a full valuation allowance against its net deferred tax assets as of December 31, 2025, indicating it is not likely to recognize these benefits[421] - Deferred tax assets increased to $8,196,960 in 2025 from $5,984,119 in 2024, primarily due to an increase in net operating loss carry-forwards[520] - The Company had U.S. federal and state net operating loss carryforwards of approximately $17,028,834 and $17,026,834 respectively as of December 31, 2025, compared to $9,235,194 and $9,234,194 in 2024[521] Subsequent Events - The Company has evaluated subsequent events through March 30, 2026, prior to the issuance of the financial statements[457] - The Company is currently assessing the impact of several recently issued Accounting Standards Updates (ASUs) on its financial statement disclosures, including ASU 2023-07 and ASU 2023-09[459][460]

IPO and Fundraising - The company completed its Initial Public Offering (IPO) on February 12, 2026, raising gross proceeds of $230 million from the sale of 23 million units at $10.00 per unit[20]. - An additional $6.65 million was raised through the sale of 665,000 Private Placement Units at $10.00 per unit, bringing total gross proceeds to $236.65 million[21]. - Following the IPO, a total of $230,000,000 was placed in a Trust Account, which may only be invested in U.S. government securities or held in cash until the completion of a Business Combination[177]. - The company has approximately $1,495,000 of proceeds held outside the Trust Account to cover costs associated with dissolution if necessary[119]. - The company has received a total of $300,000 under the IPO Promissory Note to cover expenses related to the Initial Public Offering, with $172,158 fully repaid upon IPO completion[202]. Business Combination Timeline and Requirements - The company must complete its initial Business Combination by February 12, 2028, or face termination and distribution of funds in the Trust Account[23]. - The company has until February 12, 2028, to consummate its initial business combination, with provisions for shareholder redemption if unable to do so[57]. - The company may not complete the initial Business Combination if the aggregate cash consideration required exceeds the available cash, which could lead to returning all Class A Ordinary Shares submitted for redemption[108]. - Public Shareholders may redeem their shares irrespective of their voting decision, and the redemption process will be conducted in compliance with SEC regulations[107]. - The company may seek shareholder approval to extend the Combination Period beyond February 12, 2028, which could reduce the amount held in the Trust Account and adversely affect the ability to consummate the initial Business Combination[154]. Financial Position and Revenue Generation - The company has not yet generated any operating revenues and does not expect to do so until the consummation of its initial Business Combination[19]. - The company reported a net loss of $46,064 for the period from inception (April 3, 2025) through December 31, 2025, primarily due to general and administrative costs[195]. - The company has not paid any cash dividends to date and does not intend to do so prior to completing its initial Business Combination[171]. - As of December 31, 2025, the company had a working capital deficit of $169,035 and cash held outside the Trust Account of approximately $1,665,000[200]. - The company may need additional financing to complete its initial Business Combination if the transaction requires more cash than available from the Trust Account or if significant Public Shares are redeemed[76]. Management and Strategy - The management team has a track record of completing several mergers and acquisitions, supported by their work with a reputable investment bank[38]. - The company aims to identify attractive opportunities in sectors such as AI, digital infrastructure, healthcare, and cryptocurrency across EMEA and LatAm regions[34][35]. - The management team believes that their extensive networks will provide a robust pipeline of target companies for potential investments[37]. - The company anticipates structuring its initial Business Combination to acquire 100% of the equity interests or assets of the target business, but may also acquire less than 100% if it meets certain objectives[60]. - The company expects to incur significant costs in pursuing its acquisition plans as an early-stage growth company[185]. Market Opportunities and Trends - The AI and digital infrastructure industries are projected to contribute $15.7 trillion to global GDP by 2030, with a CAGR of 36.6% from 2024 to 2030[43]. - The global sports market is expected to reach $680 billion by 2028, while the entertainment and media market is projected to exceed $3.4 trillion[43]. - U.S. healthcare expenditure is estimated to reach $5.0 trillion in 2024, with a projected EBITDA of $987 billion by 2028[43]. - The energy transition sector is projected to grow to $5.4 trillion by 2031, with a CAGR of 9.7% from 2024 to 2031[48]. - The global cryptocurrency market is expected to grow to $15.4 billion by 2032, with an annual growth rate of 13.1% from 2024 to 2032[48]. Risks and Challenges - The company may face significant dilution for public shareholders due to the conversion of Founder Shares and potential additional equity issuances[30]. - The company may face increased competition from other SPACs for attractive targets, which could lead to improved financial terms demanded by target companies[68]. - The company may lack business diversification post-initial Business Combination, relying on the performance of a single business, which could expose it to economic and regulatory risks[80][81]. - The ongoing geopolitical conflicts, including the Russia-Ukraine conflict and tensions in the Middle East, may materially adversely affect the company’s ability to find a target business for the initial Business Combination[155]. - The company may face significant risks related to cybersecurity incidents, which could adversely affect its financial condition and operations[163]. Shareholder Rights and Redemption - Public shareholders will have the opportunity to redeem their Class A Ordinary Shares at a price equal to the amount in the Trust Account, initially set at $10.00 per share[95]. - The company requires 7,291,000, or approximately 31.7%, of the 23,000,000 Public Shares sold in its Initial Public Offering to be voted in favor of the initial Business Combination for approval[102]. - A Public Shareholder holding more than 15% of the shares sold in the Initial Public Offering will be restricted from seeking redemption rights without prior consent[109]. - The decision to conduct redemptions may be made without a shareholder vote, depending on the circumstances surrounding the initial Business Combination[98]. - The company intends to require Public Shareholders to deliver share certificates or electronically transfer shares to exercise redemption rights[111]. Regulatory and Compliance Issues - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements[135]. - The company will remain an emerging growth company until it meets specific revenue or market value thresholds[137]. - The company is also classified as a "smaller reporting company," which allows for reduced disclosure obligations[138]. - Regulatory review and approval requirements may hinder the ability to complete an initial Business Combination[147]. - The company’s securities may be subject to delisting from Nasdaq, limiting Public Shareholders' ability to trade their securities[151].

Financial Results Announcement - Beeline Holdings, Inc. announced financial results for Q4 2025 on March 30, 2026[5] - The press release detailing the financial results is included as Exhibit 99.1[5] Compliance and Classification - The company is not classified as an emerging growth company under the Securities Act[4] - The filing is made in compliance with the Securities Exchange Act of 1934[10] Report Details - The report does not include any financial statements or exhibits beyond the press release[7]

Financial Performance - AEON Biopharma reported cash and cash equivalents of $3.0 million as of December 31, 2025, which does not include $4.2 million from PIPE financing received in January 2026[13]. - The company strengthened its balance sheet through $6 million PIPE financing and a note exchange, reducing outstanding debt by more than 90%[5][10]. - AEON reported a net loss of $39.2 million for the year ended December 31, 2025, compared to a net income of $42.0 million in 2024[26]. - Total operating expenses for 2025 were $12.8 million, a decrease from $73.0 million in 2024[26]. - AEON's total assets increased to $5.6 million in 2025, up from $3.1 million in 2024[24]. Product Development - The primary structure of ABP-450 exhibited a 100% sequence match to BOTOX®, based on sequence coverage of 93–99% across all five proteins[6]. - AEON plans to complete the majority of its analytical comparability program in 2026, following positive initial comparative analytical results[7][16]. - The company aims to request a BPD Type 2b meeting in 2026 to discuss the next phase of the development program for ABP-450[16]. Market Opportunity - AEON's U.S. therapeutic neurotoxin market opportunity exceeds $3.0 billion annually, representing a significant potential for biosimilar entry[17]. Leadership Changes - The company appointed John Bencich as Chief Financial Officer in March 2026, bringing over 25 years of experience in corporate strategy and capital markets[11].